Skip to main content
. 2018 Aug 31;9(68):32984–32996. doi: 10.18632/oncotarget.26034

Figure 5. Gal-1 plasma levels in PDA patients displaying short-(<6 months) or long-term survival (≥6 months).

Figure 5